Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye drug Vabysmo.
Jason Ehrlich, Ollin Biosciences CEO
June 24, 2026 07:00 AM EDT
FinancingStartups
Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China
Lei Lei Wu
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a…
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3…
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
